Business Context and Reporting Period
This Form 8-K was filed by Ocular Therapeutix, Inc. on June 21, 2019. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Bedford, MA. The report details a regulatory milestone regarding its lead product, DEXTENZA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance metrics.
Material Changes
On June 21, 2019, the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for DEXTENZA. This approval added the treatment of ocular inflammation following ophthalmic surgery as a new indication. Previously approved in November 2018 for ocular pain, DEXTENZA is now indicated for both ocular inflammation and pain following ophthalmic surgery.
Outlook, Risks, and Product Details
- Product Mechanism: DEXTENZA is the first FDA-approved intracanalicular insert, delivering 0.4mg of dexamethasone to the eye surface for up to 30 days without the need for eye drops. It is preservative-free and resorbable.
- Safety Profile: Based on clinical trials involving 567 subjects, the most common ocular adverse reactions included anterior chamber inflammation (10%), increased intraocular pressure (6%), and reduced visual acuity (2%).
- Contraindications: The product is contraindicated in patients with active corneal, conjunctival, or canalicular infections, including herpes simplex keratitis, mycobacterial infections, and fungal diseases.
- Risks: Prolonged use may result in glaucoma, optic nerve damage, and visual defects. Steroids may also suppress host response to infections and delay wound healing after cataract surgery.
Investor Verification Checklist
- Confirm the commercial launch timeline for the new ocular inflammation indication.
- Review the company's updated sales force strategy to address the expanded indication.
- Monitor post-market safety data regarding intraocular pressure and anterior chamber inflammation.
- Verify the competitive landscape for post-surgical ocular inflammation treatments.